Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.

PI Croucher, CM Shipman, MJ Perry, J Lippitt, K Asosingh, EJR van Beek, B Van Camp, GG Russell, C Dunstan, K Vanderkerken

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)761A-761A
Number of pages1
Issue number11
Publication statusPublished - 16 Nov 2000

Cite this